JP2010501188A5 - - Google Patents

Download PDF

Info

Publication number
JP2010501188A5
JP2010501188A5 JP2009525796A JP2009525796A JP2010501188A5 JP 2010501188 A5 JP2010501188 A5 JP 2010501188A5 JP 2009525796 A JP2009525796 A JP 2009525796A JP 2009525796 A JP2009525796 A JP 2009525796A JP 2010501188 A5 JP2010501188 A5 JP 2010501188A5
Authority
JP
Japan
Prior art keywords
composition
rna molecule
interfering rna
nucleotides
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009525796A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010501188A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/076776 external-priority patent/WO2008024983A2/en
Publication of JP2010501188A publication Critical patent/JP2010501188A/ja
Publication of JP2010501188A5 publication Critical patent/JP2010501188A5/ja
Pending legal-status Critical Current

Links

JP2009525796A 2006-08-24 2007-08-24 IOPに関連した病態の処置のためのグレムリンのRNAi媒介阻害 Pending JP2010501188A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83982606P 2006-08-24 2006-08-24
PCT/US2007/076776 WO2008024983A2 (en) 2006-08-24 2007-08-24 Rnai-mediated inhibition of gremlin for treatment of iop-related conditions

Publications (2)

Publication Number Publication Date
JP2010501188A JP2010501188A (ja) 2010-01-21
JP2010501188A5 true JP2010501188A5 (https=) 2010-08-12

Family

ID=39032079

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009525796A Pending JP2010501188A (ja) 2006-08-24 2007-08-24 IOPに関連した病態の処置のためのグレムリンのRNAi媒介阻害

Country Status (11)

Country Link
US (3) US20080051361A1 (https=)
EP (1) EP2059597A2 (https=)
JP (1) JP2010501188A (https=)
KR (1) KR20090042297A (https=)
CN (2) CN102743767A (https=)
AU (1) AU2007286545A1 (https=)
BR (1) BRPI0715821A2 (https=)
CA (1) CA2659464A1 (https=)
MX (1) MX2009001896A (https=)
WO (1) WO2008024983A2 (https=)
ZA (1) ZA200900553B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
GB0708662D0 (en) * 2007-05-04 2007-06-13 Galapagos Nv shRNA sequences
RU2010117178A (ru) * 2007-10-01 2011-11-10 Алькон Рисерч, Лтд. (Us) Опосредованная самокомплементарными aav доставка молекул, интерферирующих рнк для лечения или профилактики глазных заболеваний
BRPI0802525A2 (pt) 2008-07-11 2010-03-09 Kiyoshi Hashiba endoscópio cirúrgico
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
EP2510098B1 (en) * 2009-12-09 2015-02-11 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the cns
CN106074591B (zh) 2010-03-24 2020-01-14 菲奥医药公司 眼部症候中的rna干扰
KR101722948B1 (ko) 2012-01-05 2017-04-04 (주)바이오니아 리간드가 결합된 이중나선 올리고 rna 구조체 및 그 제조방법
CA2859127C (en) 2011-12-15 2017-04-25 Bioneer Corporation Novel oligonucleotide conjugates and use thereof
CN104114704A (zh) 2012-01-05 2014-10-22 株式会社百奥尼 高效率的纳米颗粒型双螺旋寡rna结构体及其制备方法
WO2013109057A1 (ko) 2012-01-18 2013-07-25 (주)바이오니아 자성나노입자-samirna 복합체 및 그 제조방법
JP6339063B2 (ja) 2012-03-15 2018-06-06 エスエヌユー アールアンドディービー ファウンデーション グレムリン−1に対する抗体
SG11201501385UA (en) * 2012-09-05 2015-03-30 Sylentis Sau Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions
GB201215857D0 (en) * 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
CN105705638B (zh) 2013-07-05 2019-11-26 柏业公司 改善的具有高效能的纳米颗粒型寡核苷酸结构及其制备方法
US10011837B2 (en) 2014-03-04 2018-07-03 Sylentis Sau SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
JP2017200928A (ja) * 2017-05-31 2017-11-09 シレンティス・エセ・ア・ウ siRNAならびに眼の状態の処置および/または予防のための方法および組成物におけるその使用
CN106978509B (zh) * 2017-06-07 2018-10-26 中南大学湘雅二医院 青光眼诊断分子标记物lncRNAs ENST00000607393、试剂盒及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101072867B1 (ko) * 2001-10-31 2011-10-17 유니버시티 오브 노스 텍사스 헬스 사이언스 센터 뼈 형태발생 단백질(bmp), bmp 수용체 및 bmp 결합 단백질 및 녹내장 진단 및 치료에서 그의 용도
US20040138163A1 (en) * 2002-05-29 2004-07-15 Mcswiggen James RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
TW200639252A (en) * 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular hypertension targets

Similar Documents

Publication Publication Date Title
JP2010501188A5 (https=)
RU2008130857A (ru) Опосредованное phkи ингибирование hif1a для лечения глазного ангиогенеза
RU2008150324A (ru) Iphk-опосредованное ингибирование связанных с фактором некроза опухоли альфа состояний
RU2011124528A (ru) ОПОСРЕДОВАННОЕ PHKI ИНГИБИРОВАНИЕ Rho-КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГЛАЗНЫХ НАРУШЕНИЙ
JP2008525460A5 (https=)
Guzman‐Aranguez et al. Small‐interfering RNA s (siRNA s) as a promising tool for ocular therapy
RU2007132874A (ru) Phki-опосредованное ингибирование мишеней повышенного внутриглазного давления
JP6752151B2 (ja) 遺伝子サイレンシングにおいて低下したoff−target効果を有するunaオリゴマー
JP2009533475A5 (https=)
JP2009540011A5 (https=)
JP2012072152A5 (https=)
US20100305193A1 (en) Rnai-mediated inhibition of gremlin for treatment of iop-related conditions
JP2010540564A5 (https=)
JP2006505251A5 (https=)
JP2022185052A5 (https=)
RU2010117178A (ru) Опосредованная самокомплементарными aav доставка молекул, интерферирующих рнк для лечения или профилактики глазных заболеваний
JP2013540770A5 (https=)
JP2008533050A5 (https=)
JP2022501044A5 (https=)
US20150057336A1 (en) RNAi-RELATED INHIBITION OF TNF alpha SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA
US20110190376A1 (en) RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF MACULAR EDEMA
JP2009533466A5 (https=)
WO2015030616A4 (en) Use of nucleic acid molecules in therapy of diseases induced by expansion of trinucleotide cag repeats
CN101124322B (zh) 用于治疗青光眼的血清淀粉状蛋白A的RNAi抑制
WO2008092142A2 (en) Rnai-mediated inhibition of aquaporin 1 for treatment of ocular neovascularization